Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic empagliflozin + linagliptin 10/5 mg vs Glyxambi 10/5 mg in healthy Thai volunteers (fasting)
TCTR20251010003Phase 1Active, not recruiting
- Sponsor
- International Bio Service
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Started Jan 2026; status: active, not recruiting.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20251010003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251010003.